Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Beauchamp

Showing results (241-250 of 244) with videos related to

Pageof 25
Sort By:
You have reached the last page of results.This site can display upto 244 results.
Plos One|June 14, 2018
Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2, Robert Allaway, Steve P Angus, et al.
Plos One|July 15, 2021
Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALKLong-Sheng Chang, Janet L Oblinger, Abbi E Smith, et al.
Medrxiv : the Preprint Server for Health Sciences|March 11, 2026
Clinical, <i>in vitro,</i> and <i>in vivo</i> evidence of <i>WAPL</i> as a novel cohesinopathy gene and phenotypic driver of 10q22.3q23.2 genomic disorderPhilip M Boone, Serkan Erdin, Abucar Mohamed, et al.
American Journal of Human Genetics|July 10, 2026
Clinical, in vitro, and in vivo evidence of WAPL as a cohesinopathy-associated gene and phenotypic driver of 10q22.3q23.2 genomic disorderPhilip M Boone, Serkan Erdin, Abucar Mohamed, et al.
Pageof 25

Showing results (241-250 of 244) with videos related to

Sort By:
Pageof 25
You have reached the last page of results.This site can display upto 244 results.
Plos One|June 14, 2018
Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2, Robert Allaway, Steve P Angus, et al.
Plos One|July 15, 2021
Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALKLong-Sheng Chang, Janet L Oblinger, Abbi E Smith, et al.
Medrxiv : the Preprint Server for Health Sciences|March 11, 2026
Clinical, <i>in vitro,</i> and <i>in vivo</i> evidence of <i>WAPL</i> as a novel cohesinopathy gene and phenotypic driver of 10q22.3q23.2 genomic disorderPhilip M Boone, Serkan Erdin, Abucar Mohamed, et al.
American Journal of Human Genetics|July 10, 2026
Clinical, in vitro, and in vivo evidence of WAPL as a cohesinopathy-associated gene and phenotypic driver of 10q22.3q23.2 genomic disorderPhilip M Boone, Serkan Erdin, Abucar Mohamed, et al.
Pageof 25